{
    "pmid": "41450930",
    "title": "Outcomes with frontline immune checkpoint inhibitors among individuals with ",
    "abstract": "Oncogenic  We retrospectively analyzed patients with  Among 122 individuals, 54 had Class I and 68 had non-Class I mutations. For Class I mutations, ICIs yielded a PFS of 9.2 months and OS of 42.2 months, representing a significant OS advantage over chemotherapy-alone (22.2 months;  ICIs appear effective in ",
    "disease": "lung cancer",
    "clean_text": "outcomes with frontline immune checkpoint inhibitors among individuals with oncogenic we retrospectively analyzed patients with among individuals had class i and had non class i mutations for class i mutations icis yielded a pfs of months and os of months representing a significant os advantage over chemotherapy alone months icis appear effective in"
}